Eli Lilly & Co. vs ResMed Inc.
LLY vs RMD — side-by-side comparison from reported financials. LLY leads 7, RMD leads 4 of 11 comparable metrics.
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
ResMed Inc.
RMD · Healthcare
$230.05+1.46%Mixed
| Metric | LLY | RMD |
|---|---|---|
| Price | $1 177.20 | $230.05 |
| Market cap | $1.05T | $32.4B |
| Revenue (TTM) | $79.7B | $5.65B |
| Revenue growth | +31.7% | +10.2% |
| Net margin | 33.5% | 26.9% |
| Free cash flow | $18.2B | $1.65B |
| Net cash (debt) | ($35.2B) | $643M |
| 1-year price return | +37.6% | -17.2% |
| P/E | 41.6 | 21.2 |
| P/E vs own history (cheap-side %) | 88% | 91% |
| Dividend yield | 0.52% | 1.08% |
| Return on equity | 93% | 24% |
| Altman Z-score | 7.10 | — |
| CV checks passed | 11 of 11 | 10 of 11 |
| Employees | 50,000 | 11,370 |
Full résumé-style profiles: LLY CV · RMD CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.